Danazol and Liver Damage

Pearson, Kay; Zimmerman, HymanJ.

doi:10.1016/s0140-6736(80)91134-4

Cited by 37 publications

(12 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, this therapy was not associated with drug-induced alteration o f liver function parameters, which is one o f the common side effects observed with oral DZ treatment [13]. During our clinical study, none o f the patients administered DZS showed changes in hepatic transaminase levels, however, 3 pa tients o f the control group showed a marked increase in hepatic transaminase levels.…”

Section: Discussionmentioning

confidence: 59%

Danazol Suspension Injected into the Uterine Cervix of Patients with Adenomyosis and Myoma

Takebayashi

Fujino

Umesaki

et al. 1995

Gynecol Obstet Invest

View full text Add to dashboard Cite

We investigated the effect of local injections of danazol suspension (DZS) into the uterine cervix. In the cervix, danazol (DZ) reached high concentrations 1 and 4–6 h after injection; then it decreased. In the endometrium, the DZ level reached a peak 1 h after injection, and then declined. On the other hand, the DZ concentration tended to increase with time after injection in ovarian tissue and it remained at a relatively constant level for more than 2 days. During treatment with DZS, various subjective symptoms and clinical findings gradually improved from the 4th week after the start of injection onward. Moreover, an improvement of subjective symptoms was observed in all the patients by the 24th week.

show abstract

Section: Discussionmentioning

confidence: 59%

Danazol Suspension Injected into the Uterine Cervix of Patients with Adenomyosis and Myoma

Takebayashi

Fujino

Umesaki

et al. 1995

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Interestingly, however, the uterine adenomyosis in our patient was eliminated not by danazol, but by anastrozole. Although it is possible that the lesion would have shrunk with an increased dose of danazol, this was not attempted for fear of body weight increase in the obese patient and the risk of hepatic functional failure and thrombosis (10,11). In our case, a standard dose of an aromatase inhibitor, administered concomitantly with a GnRH agonist, was more effective than a standard dose of danazol.…”

Section: Discussionmentioning

confidence: 79%

Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist

Kimura

Takahashi

Takebayashi

et al. 2007

Fertility and Sterility

View full text Add to dashboard Cite

“…22 Although, in the present case, the elder brother developed severe hepatic complications, the younger brother so far has none. 12,25 It may, therefore, be important to monitor hepatic complications carefully when managing patients with DC, especially in those treated with an androgen agent. Androgens, such as danazol, have been used for decades in the treatment of AA.…”

Section: Discussionmentioning

confidence: 99%

Dyskeratosis Congenita Complicated by Hepatic Fibrosis With Hepatic Vein Thrombosis

Yoshida

Imamura²,

Sakamoto³

et al. 2014

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

We describe the case of 2 male siblings with dyskeratosis congenita (DC). Extensive genetic analysis failed to identify a causative genetic abnormality. The elder brother developed hepatic fibrosis accompanied with hepatic vein thrombosis at the age of 9 years. Recent studies have found that patients with DC sometimes develop hepatic complications, including cirrhosis. However, little is known about hepatic complications in patients with DC who lack these mutations. Further genetic studies are required to understand the relationship between DC and hepatic complications. In addition, although danazol can sometimes be effective for treating bone marrow failure, hepatotoxicity can be a major complication. Therefore, when danazol is administered to patients with DC, careful monitoring for hepatic complications is important.

show abstract

Danazol and Liver Damage

Cited by 37 publications

References 2 publications

Danazol Suspension Injected into the Uterine Cervix of Patients with Adenomyosis and Myoma

Danazol Suspension Injected into the Uterine Cervix of Patients with Adenomyosis and Myoma

Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist

Dyskeratosis Congenita Complicated by Hepatic Fibrosis With Hepatic Vein Thrombosis

Contact Info

Product

Resources

About